These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23952509)

  • 1. Substitution treatment in the era of "recovery": An analysis of stakeholder roles and policy windows in Britain.
    Duke K; Herring R; Thickett A; Thom B
    Subst Use Misuse; 2013 Aug; 48(11):966-76. PubMed ID: 23952509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of evidence and the expert in contemporary processes of governance: the case of opioid substitution treatment policy in England.
    Duke K; Thom B
    Int J Drug Policy; 2014 Sep; 25(5):964-71. PubMed ID: 24582381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary on "Substitution treatment in the era of 'recovery': an analysis of stakeholder roles and policy windows in Britain".
    Neale J
    Subst Use Misuse; 2013 Aug; 48(11):1059-60. PubMed ID: 23952515
    [No Abstract]   [Full Text] [Related]  

  • 4. Shifts in opioid substitution treatment policy in Denmark from 2000-2011.
    Frank VA; Bjerge B; Houborg E
    Subst Use Misuse; 2013 Aug; 48(11):997-1009. PubMed ID: 23952511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stakeholders in opioid substitution treatment policy: similarities and differences in six European countries.
    Thom B; Duke K; Frank VA; Bjerge B
    Subst Use Misuse; 2013 Aug; 48(11):933-42. PubMed ID: 23952506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Walking through mud; history of the Polish methadone maintenance treatment from its stakeholders' perspective.
    Moskalewicz J; Welbel M
    Subst Use Misuse; 2013 Aug; 48(11):977-96. PubMed ID: 23952510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Power and Agenda-Setting in Tanzanian Health Policy: An Analysis of Stakeholder Perspectives.
    Fischer SE; Strandberg-Larsen M
    Int J Health Policy Manag; 2016 Feb; 5(6):355-63. PubMed ID: 27285513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behind the scenes: the justifications for opioid maintenance treatment in Finland.
    Perälä R; Hellman M; Leppo A
    Subst Use Misuse; 2013 Aug; 48(11):954-65. PubMed ID: 23952508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methadone is no panacea.
    Spence D
    BMJ; 2012 Aug; 345():e5670. PubMed ID: 22915733
    [No Abstract]   [Full Text] [Related]  

  • 10. Stakeholders' role in contemporary "substitute drug" prescribing policies in Italy.
    Beccaria F; Rolando S
    Subst Use Misuse; 2013 Aug; 48(11):943-53. PubMed ID: 23952507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication-assisted recovery from opioid addiction: historical and contemporary perspectives.
    White WL
    J Addict Dis; 2012; 31(3):199-206. PubMed ID: 22873182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing an advocacy agenda for increasing access to opioid substitution therapy as part of comprehensive services for people who use drugs in South Africa.
    Scheibe A; Marks M; Shelly S; Gerardy T; Domingo AK; Hugo J
    S Afr Med J; 2018 Oct; 108(10):800-802. PubMed ID: 30421704
    [No Abstract]   [Full Text] [Related]  

  • 13. Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared.
    McKeganey N; Russell C; Cockayne L
    J Subst Abuse Treat; 2013 Jan; 44(1):97-102. PubMed ID: 22703715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piecing together stakeholder puzzles-puzzling about (opioid substitute treatment---OST) stakeholders and their pieces: a rambling point-of-view.
    Einstein S
    Subst Use Misuse; 2013 Aug; 48(11):1024-58. PubMed ID: 23952514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal cancer prevention policies in Iran: A policy analysis of agenda-setting using Kingdon's multiple streams.
    Kabiri N; Khodayari-Zarnaq R; Khoshbaten M; Arab-Zozani M; Janati A
    J Cancer Policy; 2021 Mar; 27():100265. PubMed ID: 35559940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tracing the justifications of opioid maintenance treatment in Finland.
    Selin J
    Subst Use Misuse; 2013 Aug; 48(11):1067-8. PubMed ID: 23952519
    [No Abstract]   [Full Text] [Related]  

  • 17. Substance, structure and stigma: parents in the UK accounting for opioid substitution therapy during the antenatal and postnatal periods.
    Chandler A; Whittaker A; Cunningham-Burley S; Williams N; McGorm K; Mathews G
    Int J Drug Policy; 2013 Nov; 24(6):e35-42. PubMed ID: 23688832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accessibility versus quality of care plus retention: the formula for service delivery in Australian opioid replacement therapy?
    Harlow W; Roman MW; Happell B; Browne G
    Issues Ment Health Nurs; 2013 Sep; 34(9):706-14. PubMed ID: 24004365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid substitution treatment in New Zealand: a 40 year perspective.
    Deering D; Sellman JD; Adamson S
    N Z Med J; 2014 Jul; 127(1397):57-66. PubMed ID: 24997702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary on "Stakeholders' role in contemporary 'substitute drug' prescribing policies in Italy" by Franca Beccaria and Sara Rolando.
    Minutillo A; Zuccaro P
    Subst Use Misuse; 2013 Aug; 48(11):1065-6. PubMed ID: 23952518
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.